Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Conditions:   Functioning Lung Carcinoid Tumor;   Locally Advanced Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Neuroendocrine Neoplasm;   Lung Typical Carcinoid Tumor;   Metastatic Lung Neuroendocrine Neoplasm;   Non-Functioning Lung Carcinoid Tumor;   Rec urrent Lung Neuroendocrine Neoplasm;   Unresectable Lung Neuroendocrine Neoplasm Interventions:   Drug: Everolimus;   Drug: Lutetium Lu 177 Dotatate Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials